Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesAlto Neuroscience, Inc.

Alto Neuroscience, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
31.15 USD 2.54 ( 8.88%)
Last update at 2026-11-11T21:00:00Z
VOLUME
1221855
Market Cap
957.99M

Momentum Score

…

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
28.88
Low
31.30
High
52 Week Price Range
2.12
Low
28.11
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Alto Neuroscience develops biomarker-driven tools to guide treatment selection in psychiatric disorders using biological measurements and machine learning to reduce trial-and-error prescribing. Long-term growth drivers include large unmet need in mental health, clinical validation and regulatory clearance of its predictive tests, and partnerships with biopharma and payors to commercialize diagnostics, which may support scaling.
Principal risks are early-stage commercialization with limited revenue, dependence on clinical and regulatory validation, reimbursement uncertainty, competition, and potential capital needs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
28.61
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.03
ROE
-41.80%
Net Debt
-172.08M
ROCE
-38.28%
Diluted EPS TTM
-2.19

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -63.24M -61.43M -36.30M -27.71M -9.19M
Net income -63.24M -61.43M -36.30M -27.71M -9.19M
Selling general administrative 20.75M 21.61M 7.52M 5.50M 3.90M
Selling and marketing expenses - - 0.37M 0.34M 0.14M
Gross profit -0.66M -0.50M -0.37M -0.34M 0.07M
Reconciled depreciation 0.66M 0.50M 0.37M 0.34M 0.14M
Ebit -66.36M -62.81M -34.94M -27.71M -9.19M
Ebitda -65.70M -68.61M -34.56M -27.37M -9.04M
Depreciation and amortization 0.66M -5.80M 0.37M 0.34M 0.14M
Operating income -66.36M -68.61M -37.81M -29.19M -12.06M
Other operating expenses 66.36M 68.61M 37.81M 29.19M 12.27M
Interest expense 2.47M 1.38M 1.37M 0.00M -
Interest income 6.60M 8.85M 2.35M 0.11M 0.00M
Net interest income 4.13M 7.48M 0.98M 0.11M 0.00M
Income tax expense - -61.43M - - -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.21M
Total operating expenses 65.70M 68.11M 37.81M 28.85M 12.12M
Cost of revenue 0.66M 0.50M 0.37M 0.34M 0.14M
Total other income expense net 3.13M 7.18M 1.50M 1.48M 2.87M
Net income from continuing ops -63.24M -61.43M -36.30M -27.71M -9.19M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 184.69M 177.54M 86.63M 50.85M 28.79M
Other current assets 1.23M 1.11M 2.83M 0.33M 0.24M
Total liab 33.55M 26.08M 158.30M 89.26M 41.27M
Total stockholder equity 151.14M 151.46M -71.67M -38.41M -12.48M
Other current liab 8.86M 7.56M 4.41M 3.67M 1.21M
Common stock 0.00M 0.00M - 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -201.63M -138.40M -76.97M -40.66M -12.95M
Other assets - - 0.00M - 0.00M
Cash 176.48M 168.23M 82.55M 48.34M 25.70M
Total current liabilities 11.32M 10.01M 5.61M 5.56M 1.81M
Net debt -172.08M -151.28M -72.56M 33.76M 12.46M
Short term debt 0.58M - 0.12M 0.28M -
Short long term debt 0.58M - - - -
Short long term debt total 4.41M 16.94M 9.99M 82.11M 38.16M
Other stockholder equity 352.75M 289.95M 5.37M 2.30M 0.49M
Total current assets 177.72M 169.34M 85.39M 49.22M 27.68M
Net receivables - - 0.01M 0.55M 1.74M
Long term debt 18.40M 11.56M 9.86M 9.46M -
Inventory - - - - 0.00M
Accounts payable 1.88M 1.58M 1.07M 1.61M 0.60M
Accumulated other comprehensive income 0.02M -0.10M -0.08M -0.05M -0.02M
Non currrent assets other 0.34M 0.50M 0.13M 0.06M 0.05M
Non current assets total 6.97M 8.21M 1.24M 1.63M 1.11M
Capital lease obligations 4.97M 5.39M 0.12M 0.28M 0.00M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments - -2.08M -0.47M -0.73M -0.68M
Total cashflows from investing activities -0.02M -2.08M - - -
Net borrowings 9.47M 0.00M - - -
Total cash from financing activities 60.08M 135.69M 68.13M 43.79M 31.69M
Net income -63.24M -61.43M -36.30M -27.71M -9.19M
Change in cash 8.26M 86.18M 34.20M 22.64M 21.70M
Begin period cash flow 168.73M 82.55M 48.34M 25.70M 4.01M
End period cash flow 176.98M 168.73M 82.55M 48.34M 25.70M
Total cash from operating activities -51.77M -47.42M -33.45M -20.39M -9.26M
Issuance of capital stock 50.00M 137.58M 70.18M 34.30M 31.89M
Depreciation 0.66M 0.50M 0.37M 0.34M 0.14M
Change to account receivables - - 0.33M 1.16M -1.28M
Sale purchase of stock -0.17M 0.00M - - -
Other cashflows from financing activities 60.08M -3.14M 67.95M 33.92M 31.68M
Capital expenditures 0.02M 2.08M 0.47M 0.73M 0.68M
Change in working capital 0.03M 4.06M -0.70M 4.58M -0.57M
Stock based compensation 8.11M 7.63M 2.89M 1.76M 0.23M
Other non cash items 2.67M 1.81M 0.29M 0.92M 1.47M
Free cash flow -51.79M -49.50M -33.92M -21.13M -9.94M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
ANRO
Alto Neuroscience, Inc.		 2.54
8.88%		 31.15 - - - 6.34
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Alto Neuroscience, Inc.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

650 Castro Street, Mountain View, CA, United States, 94041

650 200 0412

https://www.altoneuroscience.com

68

Name Title Year Born
Mr. Fadi Abdel M.D. Senior Vice President of Innovation 1979
Dr. Amit Etkin M.D., Ph.D. Founder, Chairman of the Board, CEO & President 1977
Mr. Nicholas C. Smith CFO & Secretary 1989
Mr. Adam Savitz M.D., Ph.D. Chief Medical Officer 1966
Mr. Michael C. Hanley M.B.A. Chief Operating Officer 1973
Ms. Melissa Berman Vice President of Finance & Accounting 1980
Ms. Erin R. McQuade J.D. General Counsel & Chief Administrative Officer 1975
Ms. Jessica Powell Chief Development Officer 1975
Mr. Nicholas C. Smith CFO & Chief Business Officer 1989
Mr. Dan Segal B.Sc. (Hons), BCom, CA, MSc Co-Founder & Strategic Advisor 1962

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…